BPC-157 vs GHK-Cu: A Research Comparison
Quick Summary
BPC-157 and GHK-Cu are two of the most-cited regenerative research peptides, but they operate through fundamentally different mechanism families. BPC-157 acts on the VEGFR2 / FAK-paxillin / NO axis as a synthetic gastric pentadecapeptide. GHK-Cu is a naturally occurring copper-binding tripeptide that modulates expression across more than 4,000 human genes. Researchers contrast them to design experiments that map mechanism family to endpoint.
BPC-157
Overview BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2] Originally isolated by Dr....
GHK-Cu
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
BPC-157 and GHK-Cu are both standard reference compounds in regenerative-peptide research literature, and both have been studied across dermal, connective-tissue, and tissue-repair research models. Despite the overlapping research applications, the two molecules represent two distinct mechanism families: BPC-157 acts as an exogenous receptor and pathway agonist; GHK-Cu acts as a copper-delivery tripeptide and broad transcriptional modulator.
This page contrasts the two compounds across structural design, mechanism family, primary research applications, common research stack pairings, and the SKU sizes Pure U.S. Peptides supplies. Researchers compare BPC-157 and GHK-Cu most often when designing experiments in tissue-repair research models where the choice of mechanism family materially shapes the readout β for example, choosing between a VEGFR2-driven angiogenesis design (BPC-157) and a transcriptional-program design with copper-cofactor delivery (GHK-Cu).
Side-by-Side: BPC-157 vs GHK-Cu
| Property | BPC-157 | GHK-Cu |
|---|---|---|
| Compound class | Synthetic pentadecapeptide (gastric-juice derivative) | Naturally occurring tripeptide-copper complex |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa) | Gly-His-Lys + Cu(II) (3 aa + copper) |
| Reported half-life | <30 min (IV/IM in research) | Short plasma half-life; copper-bound complex regenerated in plasma |
| Primary mechanism family | VEGFR2 / Akt / eNOS, FAK-paxillin, NO bidirectional modulation | Broad transcriptional modulation (4,000+ genes), copper-cofactor delivery, SOD/lysyl-oxidase support |
| Primary research applications | GI-tract repair, tendon/ligament, peripheral nerve, angiogenesis assays | Dermal repair, collagen synthesis, hair-follicle research, antioxidant SOD research |
| Common research stack pairings | TB-500, KPV, BPC-157 + GHK-Cu (regenerative blend) | BPC-157, TB-500, KPV (in GLOW / KLOW blends) |
| SKU sizes available | 5 mg, 10 mg vials | 50 mg, 100 mg vials |
| Indicative price range | $$ | $$ |
How the Two Peptides Differ Mechanistically
BPC-157 is a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of a Body Protection Compound protein originally isolated from human gastric juice. Published research identifies several converging mechanism layers: activation and internalization of VEGFR2 on endothelial cells, downstream Akt-eNOS signaling that produces nitric oxide and supports angiogenesis, and engagement of the FAK-paxillin pathway in tendon and connective-tissue fibroblasts during cell migration and adhesion.[1][2][3] A polyproline-II helix structural motif has been proposed as the basis for BPC-157 engagement of Src-family kinase SH3 domains, providing a possible intracellular signaling layer.[4] BPC-157 also exhibits bidirectional modulation of the nitric-oxide system in research models β counteracting both NOS inhibition and NOS substrate excess β consistent with a homeostatic-buffer rather than strict-agonist role.
GHK-Cu is a naturally occurring tripeptide (Gly-His-Lys) that chelates a copper(II) ion in a distorted square-planar pyramid geometry. The copper-binding configuration is central to function: GHK-Cu acts as a copper-delivery vehicle to cells while simultaneously binding to and modulating expression of more than 4,000 human genes in published microarray research.[5][6] Major transcriptional programs influenced include collagen and decorin synthesis, antioxidant superoxide-dismutase upregulation, TGF-Ξ²-superfamily modulation, and DNA-repair pathway activation. Unlike BPC-157, GHK-Cu does not act primarily through a single receptor; rather, it modulates broad transcriptional programs and serves as a copper-cofactor delivery mechanism for copper-dependent enzymes (lysyl oxidase, superoxide dismutase, others).
The mechanistic point of difference is therefore architectural. BPC-157 is a multi-pathway receptor and signaling agonist with an established VEGFR2 / FAK / NO axis. GHK-Cu is a transcriptional modulator with broad gene-expression coverage and copper-cofactor delivery β its mechanism family is closer to a metallopeptide than to a classical receptor agonist.
Research Applications Compared
BPC-157 is most-cited in research on gastrointestinal-tract repair (the original research context, with reported endpoints across gastric, intestinal, and colonic models), tendon and ligament repair (FAK-paxillin and growth-hormone-receptor-upregulation endpoints in fibroblast research), nerve repair in peripheral and central research models, and angiogenesis assays driven by VEGFR2 activation.[1][3] A characteristic research feature is its reported stability in gastric juice, which permits oral-route research designs (uncommon for peptides) in addition to subcutaneous, intraperitoneal, and topical formats.
GHK-Cu is most-cited in research on dermal repair (collagen synthesis, decorin upregulation, anti-photoaging endpoints), hair-follicle research (vellus-to-terminal transition, follicle enlargement), antioxidant-research models (SOD activation, copper-cofactor delivery), and broad transcriptional-program research (gene-expression "reset" research in aging-cell models). Topical and subcutaneous formats dominate the literature, with extensive use in cosmetic and dermal-research applications.[5][6]
The two compounds appear together in published research stacks targeting tissue-repair endpoints β most commonly in regenerative-peptide research blends such as GLOW, where the multi-pathway VEGFR2 / FAK background of BPC-157 is layered with the copper-tripeptide transcriptional program of GHK-Cu.
Choosing Between Them
When researchers choose BPC-157
BPC-157 is the preferred research compound when the design centers on receptor- or pathway-level mechanisms β VEGFR2 activation, FAK-paxillin signaling in fibroblasts, eNOS-mediated angiogenesis, gastric-tract or tendon-repair endpoints, or peripheral-nerve research. Its gastric-juice stability also makes it the standard tool compound when an oral-route research design is required.
When researchers choose GHK-Cu
GHK-Cu is the preferred research compound when the design centers on transcriptional programs, copper-cofactor delivery, or broad gene-expression modulation β collagen synthesis, antioxidant SOD upregulation, decorin production, hair-follicle research, dermal-repair endpoints, or aging-cell gene-expression research. Topical formats are particularly well-represented in the published literature.
Chemical Properties Comparison
| Property | BPC-157 | GHK-Cu |
|---|---|---|
| Molecular Formula | CββHββNββOββ | CββHββCuNβOβ |
| Molecular Weight | 1419.556 g/mol | ~401.9 Da |
| CAS Number | 137525-51-0 | 89030-95-5 |
| Amino Acid Sequence | β | β |
| PubMed Citations | 30 referenced | 24 referenced |
Explore Full Research Profiles
BPC-157
Overview BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2] Originally isolated by Dr....
GHK-Cu
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
Frequently Asked Research Questions
How are BPC-157 and GHK-Cu mechanistically different?
+
Which compound is studied for gastrointestinal-tract research?
+
Which compound is studied for dermal and skin research?
+
Can BPC-157 and GHK-Cu be studied together?
+
What is unique about BPC-157 stability in research?
+
How does GHK-Cu deliver copper to cells?
+
What sizes does Pure U.S. Peptides supply?
+
PubMed Citations Referenced
- [1]Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID: 21548867
- [2]Hsieh MJ, et al. BPC 157 promotes endothelial cell tube formation and angiogenesis through the VEGFR2 pathway. PLoS One. 2017;12(8):e0181903. PMID: 28767746
- [3]Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. PMID: 21030672
- [4]Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 26935537
- [5]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
- [6]Pickart L, et al. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PMID: 25101282
- [7]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236731
- [8]Park JR, et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. PMID: 27517489
- [9]Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29879879
More Peptide Comparisons
For Research Use Only (RUO). This comparison is for educational and informational purposes only. All products are intended solely for in-vitro research and laboratory experimentation. Products have not been approved by the FDA for human or veterinary use. Pure U.S. Peptides does not condone or encourage the use of these products for anything other than strictly defined research applications.
Educational Scope. The mechanisms, pathways, and research applications discussed on this page describe published in-vitro, ex-vivo, and animal-model literature. They do not constitute medical advice, recommendations, or guidance for in-human use. Cited PubMed references describe preclinical research findings only. Researchers should consult their institutional review processes and original literature before designing any research study using these compounds.